Physician profile
Todd David Punim
NPI 1497829600
$4,436.89
in general payments reported to CMS, 2019-2025
21 companies · $397 in 2025
The $397 reported for 2025 was more than what 80% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $787 · 2021: $539 · 2022: $733 · 2023: $860 · 2024: $639 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,328.64 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,247.09 | 2019-2025 | Dailies Total1, Precision 1, Air Optix |
| Bausch & Lomb Americas INC. | $338.36 | 2022-2025 | Infuse, Miebo, Xiidra |
| Allergan, INC. | $206.54 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $186.08 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $157.20 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $135.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.43 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.83 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $121.73 | 2021-2024 | Acuvue |
| Abbvie INC. | $108.08 | 2022 | |
| Optos, INC. | $79.40 | 2022 | |
| Visioneering Technologies, INC. | $73.54 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $66.33 | 2021 | |
| Eyevance Pharmaceuticals LLC | $35.35 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $20.85 | 2022 | |
| Lkc Technologies, INC. | $20.20 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $16.68 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $16.67 | 2022 | |
| Glaukos Corporation | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Punim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.